Arcutis Biotherapeutics, Inc.
arcutis.comWhat Do They Do?
Sells topical creams and foam for psoriasis, atopic dermatitis, and seborrheic dermatitis through wholesalers and specialty pharmacies, and develops a biologic candidate for inflammatory skin diseases.
10-K for FY2025, filed Feb 25, 2026We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with…View ↗
We launched our lead product, ZORYVE cream 0.3%, in August 2022 after obtaining our initial FDA approval for the treatment of plaque…View ↗
In December 2023, we received FDA approval for ZORYVE foam 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and…View ↗
We also received FDA approval for, and commercially launched, ZORYVE cream 0.15% in July 2024 for the topical treatment of mild to moderate…View ↗
In September 2022, we acquired Ducentis BioTherapeutics LTD (Ducentis) and its lead asset, DS-234 (now ARQ-234), a fusion protein that is a…View ↗
The Company sells its product to its customers in the United States and Canada. The Company’s customers subsequently resell the products to…View ↗
How Do They Make Money?
Customers in the United States and Canada generally pay for product sales after delivery. The company also earns licensing revenue from agreements for topical roflumilast in Japan, Greater China, and Southeast Asia.
10-K for FY2025, filed Feb 25, 2026The Company sells its product to its customers in the United States and Canada. The Company’s customers subsequently resell the products to…View ↗
Company’s products, which typically occurs upon delivery to the customer. The Company’s payment terms are generally between 30 - 65 days.View ↗
Other revenue relates primarily to the Sato and Huadong licensing agreements. See Note 7.View ↗
In August 2023, we entered into a strategic collaboration and licensing agreement (the Huadong Agreement) for topical roflumilast in…View ↗
-
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service (Product revenue, net) ↗
$376.1M
-
10-K for FY2025, filed Feb 25, 2026
$376.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
ZORYVE cream 0.3%
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
33%
FY2022: 100%
|
ZORYVE cream 0.3%, FY2025
$121M Sources
|
Sold outright |
|
ZORYVE foam
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
49%
FY2022: 0.0%
|
ZORYVE foam, FY2025
$181.9M Sources
|
Sold outright |
|
ZORYVE cream 0.15%
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
18%
FY2022: 0.0%
|
ZORYVE cream 0.15%, FY2025
$68.3M Sources
|
Sold outright |
|
ZORYVE cream 0.05%
Sold outright
|
0.2% |
ZORYVE cream 0.05%, FY2025
$911K Sources
|
Sold outright |
Who Are Their Customers?
Wholesalers and specialty pharmacies buy the products and resell them to pharmacies, health care providers, and patients in the United States and Canada.
10-K for FY2025, filed Feb 25, 2026
Do Revenues Turn Into Profits?
No. It lost $16.1M in FY2025.
10-K for FY2025, filed Feb 25, 2026
−$12.2MView ↗
10-K for FY2025, filed Feb 25, 2026
−$16.1MView ↗
10-K for FY2025, filed Feb 25, 2026
−$6.3MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
$15MView ↗
- ▲ Now profitable
- vs −$15.9M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 5, 2026
Open tableView ↗
-
Aug 5, 2026
Raised full-year net product sales guidance
Full-year net product sales guidance rose to $525 million–$540 million.
Sources
8-K, filed Aug 5, 2026
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23%…View ↗
From pipeline to marketed products
The older report described topical roflumilast cream for atopic dermatitis and foam for seborrheic dermatitis and psoriasis as development programs; the latest report describes them as approved and commercially launched products.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026
Who Do They Compete With?
Competes with AbbVie, UCB, Amgen, Bristol Myers Squibb, Organon, Galderma Laboratories, Biocon, Johnson & Johnson, Protagonist Therapeutics, Meiji Pharma, UNION, Pfizer, Incyte, Arcotech, LEO Pharma, Sanofi, Regeneron Pharmaceuticals, Eli Lilly, Apogee Therapeutics, and Nektar Therapeutics
10-K for FY2025, filed Feb 25, 2026injected biologic therapies such as Skyrizi®, marketed by AbbVie Inc., and Bimzelex®, marketed by UCB, Inc.; non-injectable systemic…View ↗
Loading...
